Next Article in Journal
Extent and Predictors of Poor Glycaemic Control among Elderly Pakistani Patients with Type 2 Diabetes Mellitus: A Multi-Centre Cross-Sectional Study
Previous Article in Journal
Acute Proximal Myopathy in a Young Male—A Case of Infectious Myositis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 55
Issue 1
10.3390/medicina55010020
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis

by
Md. Rezanur Rahman
1,2,*,†,
Tania Islam
1,†,
Esra Gov
3,
Beste Turanli
4,5,
Gizem Gulfidan
4,
Md. Shahjaman
6,
Nilufa Akhter Banu
1,
Md. Nurul Haque Mollah
7,
Kazim Yalcin Arga
4 and
Mohammad Ali Moni
8,*
1
Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia-7003, Bangladesh
2
Department of Biochemistry and Biotechnology, School of Biomedical Science, Khwaja Yunus Ali University, Sirajgonj-6751, Bangladesh
3
Department of Bioengineering, Adana Science and Technology University, Adana-01250, Turkey
4
Department of Bioengineering, Marmara University, Istanbul-34722, Turkey
5
Department of Bioengineering, Istanbul Medeniyet University, Istanbul-34700, Turkey
6
Department of Statistics, Begum Rokeya University, Rangpur-5400, Bangladesh
7
Laboratory of Bioinformatics, Department of Statistics, University of Rajshahi, Rajshahi-6205, Bangladesh
8
The University of Sydney, Faculty of Medicine and Health, Sydney Medical School, Discipline of Biomedical Science, Sydney, NSW 2006, Australia
*
Authors to whom correspondence should be addressed.
†
These two authors have made an equal contribution and hold joint first authorship for this work.
Medicina 2019, 55(1), 20; https://doi.org/10.3390/medicina55010020
Submission received: 30 November 2018 / Revised: 23 December 2018 / Accepted: 14 January 2019 / Published: 17 January 2019
Browse Figures
Versions Notes

Abstract

:
Background and objectives: Colorectal cancer (CRC) is the second most common cause of cancer-related death in the world, but early diagnosis ameliorates the survival of CRC. This report aimed to identify molecular biomarker signatures in CRC. Materials and Methods: We analyzed two microarray datasets (GSE35279 and GSE21815) from the Gene Expression Omnibus (GEO) to identify mutual differentially expressed genes (DEGs). We integrated DEGs with protein–protein interaction and transcriptional/post-transcriptional regulatory networks to identify reporter signaling and regulatory molecules; utilized functional overrepresentation and pathway enrichment analyses to elucidate their roles in biological processes and molecular pathways; performed survival analyses to evaluate their prognostic performance; and applied drug repositioning analyses through Connectivity Map (CMap) and geneXpharma tools to hypothesize possible drug candidates targeting reporter molecules. Results: A total of 727 upregulated and 99 downregulated DEGs were detected. The PI3K/Akt signaling, Wnt signaling, extracellular matrix (ECM) interaction, and cell cycle were identified as significantly enriched pathways. Ten hub proteins (ADNP, CCND1, CD44, CDK4, CEBPB, CENPA, CENPH, CENPN, MYC, and RFC2), 10 transcription factors (ETS1, ESR1, GATA1, GATA2, GATA3, AR, YBX1, FOXP3, E2F4, and PRDM14) and two microRNAs (miRNAs) (miR-193b-3p and miR-615-3p) were detected as reporter molecules. The survival analyses through Kaplan–Meier curves indicated remarkable performance of reporter molecules in the estimation of survival probability in CRC patients. In addition, several drug candidates including anti-neoplastic and immunomodulating agents were repositioned. Conclusions: This study presents biomarker signatures at protein and RNA levels with prognostic capability in CRC. We think that the molecular signatures and candidate drugs presented in this study might be useful in future studies indenting the development of accurate diagnostic and/or prognostic biomarker screens and efficient therapeutic strategies in CRC.

1. Introduction

Colorectal cancer (CRC) is the second most common cause of mortality of men and women in the world [1]. The number of CRC cases is still increasing, and the global burden of CRC is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030 [2]. Like other cancers, a number of factors such as genetic factors, epigenetic alterations, diet, and environmental factors contribute to the progression and metastasis of CRC [3,4]. Despite the comprehensive studies (as reviewed by Reference [5]), the molecular mechanisms of CRC pathogenesis are only partially understood. Several biomarkers (KRAS and BRAF) are used to detect CRC, but these biomarkers are not sufficiently sensitive and specific; consequently, there is an urgent need for the identification of efficacious biomarkers, therapeutic targets, and agents for early diagnosis, prevention, and personalized therapy in CRC [6].
Gene expression profiling technologies were employed for years to identify genetic alterations at the transcriptional level that pave the way to candidate biomarkers in human diseases including cancers [7,8,9]. These biomarkers may be used in early detection and/or serve as novel therapeutic targets. Hundreds of differentially expressed genes (DEGs) were identified in CRC from microarray data [10,11]; however, their roles within human signaling networks and their transcriptional regulatory mechanisms via transcription factors (TFs) and microRNAs (miRNAs) were not studied in detail within a network biomedicine approach. The regulatory biomolecules might be attractive biomarkers since several reports proposed microRNAs (miRNAs) that act as key players in CRC as prognostic biomarkers [12,13].
The power of multi-omics analyses within the network biomedicine perspective [14] in the elucidation of molecular signatures in human diseases was previously shown in many human diseases such as head and neck cancers [15], esophageal squamous cell carcinoma [16], triple negative breast cancer [17], cervical cancer [18], ovarian cancer [19] and ovarian diseases [20], psoriasis [21], and type 2 diabetes [22]. Therefore, in this study, systems-based approaches were considered to explore the potential biomarker signatures at protein (i.e., hub proteins and transcription factors (TFs)) and RNA levels (i.e., miRNAs and messenger RNAs (mRNAs)) (Figure 1). For this purpose, we considered mutual DEGs identified from two independent gene expression profiling studies to maintain robustness, integrated this information with human biomolecular networks (i.e., protein–protein interaction and transcriptional/post-transcriptional regulatory networks) to identify reporter signaling and regulatory molecules, utilized functional overrepresentation and pathway enrichment analyses to elucidate the roles of reporter molecules in biological processes and molecular pathways, and performed survival analyses to evaluate their prognostic performance as potential biomarkers in CRC. In addition, several candidate drugs were repositioned in CRC using in silico drug repositioning tools, Connectivity Map (CMap) [23] and geneXpharma [24], considering these biomarker signatures as therapeutic targets.

2. Materials and Methods

2.1. High-Throughput Microarray Gene Expression Datasets

To analyze mRNA signatures in CRC samples compared to normal tissues, two gene expression datasets obtained using Agilent microarrays in independent experiments, GSE35279 [25] and GSE21815 [26], were downloaded from the Gene Expression Omnibus (GEO) database [27], which is a public functional genomics data repository supporting MIAME compliant data submissions. Consequently, a total of 220 specimens (206 CRC specimens and 14 normal samples) were comparatively analyzed.

2.2. Identification of Differentially Expressed Genes

To characterize differentially expressed genes (DEGs), each dataset was normalized by means of the robust multi-array average (RMA) expression measure [28], and DEGs were identified from the normalized log-expression values using the multiple testing option of LIMMA (linear models for microarray data) [29] using the R/Bioconductor platform (version R × 64 3.4.1). Benjamini–Hochberg’s method was used to control the false discovery rate. An adjusted p-value threshold of 0.01 with a fold-change cutoff of 2 was used to determine the statistical significance of differential expression.

2.3. Gene Ontology and Pathway Analysis

Clustering of DEGs and reporter molecules into functional groups (i.e., biological processes and molecular pathways) was performed via DAVID’s functional annotation tool [30]. In the analyses, the Kyoto Encyclopedia of Genes and Genomes (KEGG) [31] was preferably used as the pathway database and the Gene Ontology (GO) project [32] was used as the annotation source for biological processes and molecular functions. Fisher’s exact test was used to evaluate the statistical significance. The p-values were corrected via Benjamini–Hochberg’s method, and an adjusted p-value threshold (adj-p < 0.05) was used for all enrichment analyses.

2.4. Reconstruction and Analysis of Protein–Protein Interaction (PPI) Network in CRC

We recruited the previously reconstructed high-confidence PPI network of Homo sapiens [33] consisting of 288,033 physical interactions between 21,052 proteins to construct a PPI subnetwork around the proteins encoded by the identified DEGs. The subnetwork was visualized and analyzed via Cytoscape (v3.4 and 2.8.3) [34]. The topological analysis was performed to characterize the network properties through the Cyto-Hubba plugin [35]. The dual-metric approach [17,22] utilizing a local (i.e., degree) and a global (i.e., betweenness centrality) metric was simultaneously employed to define hub proteins. The modules in the PPI sub-networks were identified using MCODE plug-in [36] in Cytoscape. The modules were further analyzed through enrichment analyses in DAVID’s functional annotation tool [30].

2.5. Identification of Reporter Biomolecules

To identify reporter regulatory molecules (i.e., TFs and miRNAs) around which significant changes occur at the transcriptional level, we employed the comprehensive human transcriptional and post-transcriptional regulatory network [37], consisting of the experimentally verified TF–target gene and miRNA–target gene interactions from HTRIdb [38] and miRTarbase (Release 6.0) [39] databases. The reporter features algorithm [40] was used and implemented as described previously [15,18,20] to obtain z-scores and corresponding p-values of the molecules. The p-values were corrected via Benjamini–Hochberg’s method, and statistically significant (adj-p < 0.01) results were considered as reporter biomolecules.

2.6. Evaluation of the Prognostic Performance of Reporter Molecules

The prognostic power of reporter biomolecules (i.e., hubs, TFs, and miRNAs) was analyzed via multivariate Cox regression analysis as implemented in SurvExpress [41] and OncomiR [42], using independent gene expression (RNA sequencing (RNA-Seq) or miRNA-Seq) datasets obtained from The Cancer Genome Atlas (TGCA). The RNA-Seq dataset consisted of 467 samples with their clinical information, whereas the miRNA-Seq data included 424 patients. The patients were partitioned into low- and high-risk groups according to their prognostic index determined by SurvExpress or OncomiR. The differences in gene expression levels between the risk groups were represented via box-plots, and the statistical significance of the differences was estimated by Student’s t-test. The survival signatures of reporter biomolecules were evaluated by Kaplan–Meier plots, and a log-rank p-value < 0.05 was considered as the cut-off to describe statistical significance in all survival analyses.

2.7. Identification of Candidate Drugs

We simultaneously used the Connectivity Map (CMap) database [23] and geneXpharma tool [24] to identify potential candidate drugs. CMap stores the expression profiles from cultured human cells exposed to various small molecular agents. A total of 50,304 gene–drug interactions comprising 4344 genes and 11,939 drugs are presented in geneXpharma. The hypergeometric probability test was used to statistically associate drugs to CRC.

3. Results

3.1. Identification of Differentially Expressed Genes

We studied two microarray CRC datasets (GSE35279 and GSE21815) from independent experiments to detect DEGs dysregulated in CRC samples compared to normal tissues. The analyses presented 727 upregulated and 99 downregulated genes mutually differentiated in both CRC datasets (Figure 2). Then, we performed gene set overrepresentation analyses to obtain the GO annotations (in terms of molecular function, biological process, and cellular component) and KEGG pathways significantly associated with DEGs. The top 5 GO terms for upregulated and downregulated DEGs are summarized in Table 1, and the significant molecular pathways altered in CRC are shown in Figure 3.
The overrepresentation analyses indicated the upregulation of collagen-associated processes, extracellular matrix (ECM) organization, and male gonad development. The upregulated proteins mainly had protein-binding activities and localized in extracellular environments or the cytoplasm. On the other hand, transport process, most specifically bicarbonate and chloride transport, were downregulated in CRC. Downregulated proteins mostly involved zinc ion binding, and hormone and chloride channel activities and were localized in the integral component of the plasma membrane (Table 1). In parallel to GO enrichment results, the PI3K/Akt signaling pathway, Wnt signaling pathway, cell cycle, lung cancer, ECM–receptor interaction, protein digestion and absorption, pathways in cancer, and TGF-β signaling pathway were upregulated in CRC (Figure 3A). Contrarily, nitrogen metabolism, pancreatic secretion, axon guidance, retinol metabolism, renin secretion, and chemical carcinogenesis pathways were downregulated in CRC (Figure 3B).

3.2. Analysis of Protein–Protein Interaction Network to Identify Hub Proteins

To identify hub proteins, a PPI sub-network around proteins encoded by the DEGs was constructed, and its topological analysis was performed. Following the scale-free degree distribution and small-world properties of biological networks, the presence of 10 hub proteins (ADNP, CCND1, CD44, CDK4, CEBPB, CENPA, CENPH, CENPN, MYC, and RFC2) was detected using degree and betweenness centrality metrics. These hub proteins may play significant key roles in signal transduction during the progression of CRC (Table 2). Two functional modules were revealed from the PPI network: module 1, consisting of IPO5, RBP2, and RAN, was associated with intracellular protein transport, and module 2, consisting of CENPN, CENPA, and CENPH, was enriched with sister chromatid cohesion, and kinetochore and nucleosome assembly (data not shown).

3.3. Identification of Regulatory Biomolecules

To identify reporter regulatory molecules (i.e., TFs and miRNAs) around which significant changes occur at transcriptional level, we integrated DEGs with a human transcriptional and post-transcriptional regulatory network and employed the adopted version of reporter features algorithm [20,40] for each dataset. Considering a statistical significance level of adj-p < 0.01, we identified 10 TFs (ETS1, ESR1, GATA1, GATA2, GATA3, AR, YBX1, FOXP3, E2F4, and PRDM14) and 10 miRNAs (miR-16-5p, miR-26b-5p, miR-124-3p, let-7b-5p, miR-92a-3p, miR-192-5p, miR-155-5p, miR-93-5p, miR-193b-3p, and miR-17-5p) as the mutual transcriptional regulatory components in both CRC datasets (Table 3).

3.4. Survival Analysis of Biomolecules

We performed the survival analysis of biomolecules (i.e., 10 hubs, 10 TFs, and 10 miRNAs) using CRC datasets from TCGA. Based on expression levels of reporter biomolecules and estimated survival probabilities, the patients were partitioned into two groups (i.e., high-risk and low-risk groups). The differential gene expression levels in high- and low-risk groups were represented by the box-plots and the estimated the survival probabilities were represented by Kaplan–Meier plots. In simulations, hub proteins, reporter TFs, and reporter miRNAs were considered as separate biomarker sets.
Almost all of the hub proteins (except RFC2) contributed to the discrimination of risk groups as seen in statistical powers represented in the box-plot (Figure 4A), and the hub proteins as a group demonstrated statistically significant prognostic capability with a hazards ratio of 2.57 (log-rank p = 9.56 × 10−6) (Figure 4B). The reporter TFs (log-rank p = 0.0185) were also indicative of CRC prognosis with a hazards ratio of 1.75 (Figure 5B). Among the TFs, GATA1, GATA2, E2F4, ESR1, and PRDM14 were the major discriminators (Figure 5A). In addition, the survival analysis of a subset of reporter miRNAs, consisting of miR-193b-3p and miR-615-3p, showed a prognostic signature (log-rank p = 0.014) (Figure 6).

3.5. Identification of Candidate Drugs through In Silico Drug Repositioning

Regarding the hub proteins and TFs as potential drug targets in CRC, we identified potential drugs based on the transcriptome signatures guided drug repositioning tool, geneXpharma, and the CMap database. We considered only the common drugs between both databases for CRC. Statistical evaluation revealed 45 candidate drugs targeting six proteins (Table 4). The drugs were classified according to the anatomical sites and development stages (Figure 7). Among the 10 hub proteins considered as a drug target, three hub proteins, i.e., CCND1, CDK4, and MYC, were targeted by nine drugs (Table 4). Contrarily, among the 10 reporters TFs, three reporter TFs were targeted by 23 drugs (Table 4). The repositioned drugs were classified based on the Anatomical Therapeutic Chemical classification system and it was found that 16.12% were antineoplastic, and 22.58% were antineoplastic and immunomodulating agents. The hormones and contraceptives agents (9.67%) followed the antineoplastic and immunomodulating agents. The repositioned drugs were analyzed and it was found that 49% of drugs were approved, whereas 48% were still under investigation and 3% were in the experimental stage (Figure 7).

4. Discussion

Colorectal cancer (CRC) is a complex disease, and the molecular mechanisms of CRC pathogenesis are only partially understood. The augmenting effect of genetic, endocrinological perturbations, and epigenetic aberrations contribute to the pathobiology of CRC [4,5,6]. High-throughput gene expression profiling technology is considered as one of the efficient sources for screening of biomarker candidates [7,8,9]. Understanding the disease pathways and exploration of biomarkers requires integration of omics data from different levels, and the power of this multi-omics approach in the elucidation of molecular signatures in human diseases was previously shown in many human diseases [14,15,16,17,18,19,20,21,22]. Consequently, we employed a systems biomedicine approach to explore the in-depth mechanism of CRC in the present study.
Analysis of differential gene expression in CRC using two different high-throughput experimentations resulted in the identification of 727 upregulated and 99 downregulated DEGs. The pathway enrichment analyses revealed significant molecular pathways including Wnt signaling pathway and inflammatory signaling pathways, which were already implicated in the pathogenesis of CRC [43]. The TGF-β pathway behaves as a tumor suppressor or tumor promoter depending on context in different cancers, and TGF-β was proposed as a target for cancer therapy [44]. Considering the significant alterations in these pathways during the progression of the CRC, we propose their components of as potential therapeutic targets in CRC.
Analysis of the PPI provides insight into central mechanisms on the pathobiology of cancers [45]. The PPI networks were reconstructed in order to clarify the interaction among the identified DEGs. Several hub proteins came into prominence as the reporter signaling mediators in CRC associated PPI. The prognostic survival analysis showed that these hub genes were significantly associated with the worse survival outcomes in CRC patients (Figure 5). Among the hub proteins, ADNP is dysregulated in CRC with high Wnt activity [46]; CEBPB is afflicted with colorectal cancer and glioblastoma cells [47,48]; CCND1 dysregulation contributes to the pathogenesis of CRC [49,50]; CD44 plays diverse roles in cancer cells [51]; CDK4 is the target for different cancer treatments including colorectal cancer [51,52]; CENPA is associated in the pathobiology of CRC [53]; CENPH is also implicated in CRC [54]; RFC2 is implicated in hematologic cancers [55,56]; MYC is dysregulated in CRC [57,58,59]; CENPN is a protein that, in humans, is involved in tge cell-cycle process showing direct binding of CENPN to CENPA [60]. The modules significantly contained the nodes (i.e., CENPA, CENPN, and CENPH) which are associated with different cancers and disease progression as discussed above.
Significant TFs regulating the DEGs were also characterized. Among the reporter TFs, AR is dysregulated in the prostate cancer [61]; ETS is involved in different types of cancers [62]; GATA2 is deregulated in CRC with poor survival outcomes [63]; GATA3 and GATA4 were proposed to be implicated in different cancers [64]; YBX1 and FOXP3 are markers of cancers [65,66,67]; E2F4 disruption is involved in cancers [68,69]; the dysregulation of PRDM14 and ESR1 is found in breast cancers [70,71,72].
The expression of 500 miRNAs was determined in CRC [6]. Thus, we evaluated the biomarker potentiality of the miRNAs in CRC since they regulate genes involved in the cell cycle [12,73,74]. We identified relevant miRNA signatures (miR-193b-3p and miR-615-3p), and survival analysis showed their significant potential as biomarkers in CRC. Recently, Wu et al. found that dysregulation of miR-193b-3p affects the growth of CRC via TGF-β and regulation of the SMAD signaling pathway [75]. Our pathway enrichment results also showed the dysregulation of the TGF-β signaling pathway. Moreover, miR-193b-3p is a predictive biomarker of renal cell carcinoma [76]. The high expression of miR-615-3p is associated with the pathogenesis of CRC and gastric cancer [77,78]. Researches on these miRNAs might provide a therapeutic target for CRC.
The survival analysis of the hub genes, TFs, and miRNAs clarified that these gene signatures (MYC, CENPN, RFC, CENPA, CEBPB, ADNP, CDK4, CCND1, CENPH, and CD44) have high potentiality of being prognostic biomarkers in CRC. It was found that the high expression of reporter TF signatures (AR, GATA1, GATA2, GATA3, EST1, YBX1, PRADM14, ESR1, E2F4, and FOXP3) is associated with worse survival outcomes of the CRC patients. The survival analysis of the miRNA signatures (miR-193b-3p and miR-615-3p) also showed significant prognostic power in CRC. In addition, we here identified 45 candidate repositioned drugs, which were mostly antineoplastics, antidiabetics, and endocrinologicals.
Despite the tremendous significance of the computational finding of this present work, further experiments at the transcription and protein expression levels (such as Western blot, qRT–PCR, CRISPR/Cas9 gene editing, etc.) and in vitro and in vivo cell culture assays for potential drugs should be performed for confirmation of the above results.

5. Conclusions

We employed a well-established systems biomedicine framework where transcriptome datasets were incorporated with genome-scale human molecular networks to reveal molecular biomarker signatures at the RNA (i.e., mRNAs and miRNAs) and protein (i.e., hub proteins and TFs) levels in CRC. The prognostic survival analysis of the identified reporter biomolecules revealed proteomic signatures consisting of hub proteins (MYC, CENPN, RFC, CENPA, CEBPB, ADNP, CDK4, CCND1, CENPH, and CD44), and regulatory signatures consisting of TFs (AR, GATA1, GATA2, GATA3, EST1, YBX1, PRADM14, ESR1, E2F4, and FOXP3) and miRNAs (miR-193b-3p and miR-615-3p) as prognostic biomarker candidates in CRC. In addition, candidate repositioned drugs targeting hub proteins and TFs were identified. The identified biomarker signatures and candidate repositioned drugs in this study deserve further experimentation, since they show importance as candidate biomarkers and therapeutics for precision medicine approaches to treat CRC.

Author Contributions

Conceptualization: M.R.R., K.Y.A., and M.A.M.; formal analysis, M.R.R., T.I., E.G., B.T., G.G., M.S., and K.Y.A.; investigation, M.R.R. and T.I.; methodology, M.R.R., E.G., B.T., M.S., K.Y.A., and M.A.M.; supervision, N.A.B., M.N.H.M., K.Y.A., and M.A.M.; writing—original draft, M.R.R.; writing—review and editing, M.R.R., E.G., G.G., K.Y.A., and M.A.M.

Funding

This article did not receive any external funding.

Acknowledgments

We would like to express our thanks to the Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia, Bangladesh, and the Laboratory of Bioinformatics, Department of Statistics, University of Rajshahi, Bangladesh for providing the bioinformatics laboratory facility. This work was supported by an Islamic University research grant (2017–2018). The financial support to Kazim Yalcin Arga by the Scientific and Technological Research Council of Turkey (TUBITAK) through projects 116M014 and 117S489, and the Marmara University Research Fund (BAPKO) through projects FEN-C-DRP-250816-0417 and FEN-C-YLP-170118-0013 are acknowledged.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
  2. Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017, 66, 683–691. [Google Scholar] [CrossRef] [PubMed]
  3. Markowitz, S.D.; Bertagnolli, M.M. Molecular Basis of Colorectal Cancer. N. Engl. J. Med. 2013, 361, 2449–2460. [Google Scholar] [CrossRef] [PubMed]
  4. Kheirelseid, E.A.H.; Miller, N.; Kerin, M.J. Molecular biology of colorectal cancer: Review of the literature. Am. J. Mol. Biol. 2013, 3, 72–80. [Google Scholar] [CrossRef]
  5. Grady, W.M.; Markowitz, S.D. The molecular pathogensis of colorectal cancer and its potential application to colorectal cancer screening. Dig. Dis. Sci. 2015, 60, 762–772. [Google Scholar] [CrossRef] [PubMed]
  6. Zarkavelis, G.; Boussios, S.; Papadaki, A.; Katsanos, K.H.; Christodoulou, D.K.; Pentheroudakis, G. Current and future biomarkers in colorectal cancer. Ann. Gastroenterol. 2017, 30, 613–621. [Google Scholar] [CrossRef] [PubMed]
  7. Krizkova, S.; Kepinska, M.; Emri, G.; Rodrigo, M.A.M.; Tmejova, K.; Nerudova, D.; Kizek, R.; Adam, V. Microarray analysis of metallothioneins in human diseases—A review. J. Pharm. Biomed. Anal. 2016, 117, 464–473. [Google Scholar] [CrossRef] [Green Version]
  8. Stewart, J.P.; Richman, S.; Maughan, T.; Lawler, M.; Dunne, P.D.; Salto-Tellez, M. Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables. Biochim. Biophys. Acta 2017, 1868, 258–272. [Google Scholar] [CrossRef]
  9. Kamel, H.F.M.; Al-Amodi, H.S.A.B. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics Proteomics Bioinformatics 2017, 15, 20–35. [Google Scholar] [CrossRef]
  10. Isella, C.; Terrasi, A.; Bellomo, S.E.; Petti, C.; Galatola, G.; Muratore, A.; Mellano, A.; Senetta, R.; Cassenti, A.; Sonetto, C.; et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 2015, 47, 312–319. [Google Scholar] [CrossRef]
  11. Tripathi, M.K.; Deane, N.G.; Zhu, J.; An, H.; Mima, S.; Wang, X.; Padmanabhan, S.; Shi, Z.; Prodduturi, N.; Ciombor, K.K.; et al. Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Cancer Res. 2014, 74, 6947–6957. [Google Scholar] [CrossRef] [PubMed]
  12. Masuda, T.; Hayashi, N.; Kuroda, Y.; Ito, S.; Eguchi, H.; Mimori, K. MicroRNAs as biomarkers in colorectal cancer. Cancers (Basel) 2017, 9, 124. [Google Scholar] [CrossRef] [PubMed]
  13. Michael, M.Z.; O’ Connor, S.M.; van Holst Pellekaan, N.G.; Young, G.P.; James, R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 2003, 1, 882–891. [Google Scholar] [CrossRef] [PubMed]
  14. Barabási, A.L.; Gulbahce, N.; Loscalzo, J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 2011, 12, 56–68. [Google Scholar] [CrossRef] [PubMed]
  15. Islam, T.; Rahman, M.R.; Gov, E.; Turanli, B.; Gulfidan, G.; Haque, M.A.; Arga, K.Y.; Mollah, M.N.H. Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses. OMICS 2018, 22, 422–436. [Google Scholar] [CrossRef] [PubMed]
  16. Karagoz, K.; Lehman, H.; Stairs, D.; Sinha, R.; Arga, K.Y. Proteomic and metabolic signatures of esophageal squamous cell carcinoma. Curr. Cancer Drug Targets 2016, 16, 721–736. [Google Scholar] [CrossRef]
  17. Karagoz, K.; Sinha, R.; Arga, K.Y. Triple Negative Breast Cancer: A Multi-omics Network Discovery Strategy for Candidate Targets and Driving Pathways. OMICS 2015, 19, 115–130. [Google Scholar]
  18. Kori, M.; Arga, K.Y. Potential biomarkers and therapeutic targets in cervical cancer: Insights from meta-analysis of transcriptomics data within network biomedicine perspective. PLoS ONE 2018, 13, e0200717. [Google Scholar] [CrossRef]
  19. Gov, E.; Kori, M.; Arga, K.Y. Multiomics analysis of tumor microenvironment reveals Gata2 and miRNA-124-3p as potential novel biomarkers in ovarian cancer. OMICS 2017, 21, 603–615. [Google Scholar]
  20. Kori, M.; Gov, E.; Arga, K.Y. Molecular signatures of ovarian diseases: Insights from network medicine perspective. Syst. Biol. Reprod. Med. 2016, 62, 266–282. [Google Scholar] [CrossRef]
  21. Sevimoglu, T.; Turanli, B.; Bereketoglu, C.; Arga, K.Y.; Karadag, A.S. Systems biomarkers in psoriasis: Integrative evaluation of computational and experimental data at transcript and protein levels. Gene 2018, 647, 157–163. [Google Scholar] [CrossRef] [PubMed]
  22. Calimlioglu, B.; Karagoz, K.; Sevimoglu, T.; Kilic, E.; Gov, E.; Arga, K.Y. Tissue-Specific Molecular Biomarker Signatures of Type 2 Diabetes: An Integrative Analysis of Transcriptomics and Protein-Protein Interaction Data. OMICS 2015, 19, 563–573. [Google Scholar] [CrossRef]
  23. Lamb, J.; Crawford, E.D.; Peck, D.; Modell, J.W.; Blat, I.C.; Wrobel, M.J.; Lerner, J.; Brunet, J.P.; Subramanian, A.; Ross, K.N.; et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313, 1929–1935. [Google Scholar] [CrossRef] [PubMed]
  24. Turanli, B.; Gulfidan, G.; Arga, K.Y. Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma. OMICS 2017, 21, 584–591. [Google Scholar] [CrossRef]
  25. Kagawa, Y.; Matsumoto, S.; Kamioka, Y.; Mimori, K.; Naito, Y.; Ishii, T.; Daisuke Okuzaki, D.; Nishida, N.; Maeda, S.; Naito, A.; et al. Cell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and invasion in vivo. PLoS ONE 2013, 8, e83629. [Google Scholar] [CrossRef] [PubMed]
  26. Kogo, R.; Shimamura, T.; Mimori, K.; Kawahara, K.; Imoto, S.; Sudo, T.; Kogo, R.; Shimamura, T.; Mimori, K.; Kawahara, K.; et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011, 71, 6320–6326. [Google Scholar] [CrossRef] [PubMed]
  27. Barrett, T.; Wilhite, S.E.; Ledoux, P.; Evangelista, C.; Kim, I.F.; Tomashevsky, M.; Marshall, K.A.; Phillippy, K.H.; Sherman, P.M.; Holko, M.; et al. NCBI GEO: Archive for functional genomics data sets—Update. Nucleic Acids Res. 2013, 41, 991–995. [Google Scholar] [CrossRef]
  28. Bolstad, B.M.; Irizarry, R.A.; Astrand, M.; Speed, T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19, 185–193. [Google Scholar] [CrossRef] [Green Version]
  29. Smyth, G.K.; Ritchie, M.; Thorne, N. Linear Models for Microarray Data User’s Guide. Bioinformatics 2011, 20, 3705–3706. [Google Scholar] [CrossRef]
  30. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [Google Scholar] [CrossRef]
  31. Kanehisa, M.; Furumichi, M.; Tanabe, M.; Sato, Y.; Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017, 45, D353–D361. [Google Scholar] [CrossRef] [PubMed]
  32. The Gene Ontology Consortium. Gene Ontology Consortium: Going forward. Nucleic Acids Res. 2015, 43, D1049–D1056. [Google Scholar] [CrossRef]
  33. Karagoz, K.; Sevimoglu, T.; Arga, K.Y. Integration of multiple biological features yields high confidence human protein interactome. J. Theor. Biol. 2016, 403, 85–96. [Google Scholar] [CrossRef]
  34. Smoot, M.E.; Ono, K.; Ruscheinski, J.; Wang, P.L.; Ideker, T. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 2011, 27, 431–432. [Google Scholar] [CrossRef] [PubMed]
  35. Chin, C.H.; Chen, S.H.; Wu, H.H.; Ho, C.W.; Ko, M.T.; Lin, C.Y. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014, 8 (Suppl. 4). [Google Scholar] [CrossRef] [PubMed]
  36. Bader, G.D.; Hogue, C.W. An automated methods for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003, 4, 2. [Google Scholar] [CrossRef]
  37. Gov, E.; Arga, K.Y.A. Interactive cooperation and hierarchical operation of microRNA and transcription factor crosstalk in human transcriptional regulatory network. IET Syst. Biol. 2016, 10, 219–228. [Google Scholar] [CrossRef]
  38. Bovolenta, L.A.; Acencio, M.L.; Lemke, N. HTRIdb: An open-access database for experimentally verified human transcriptional regulation interactions. BMC Genomics 2012, 13, 405. [Google Scholar] [CrossRef]
  39. Hsu, S.D.; Tseng, Y.T.; Shrestha, S.; Lin, Y.L.; Khaleel, A.; Chou, C.H.; Chu, C.F.; Huang, H.Y.; Lin, C.M.; Ho, S.Y.; et al. miRTarBase update 2014: An information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2014, 42, D78–D85; [Google Scholar] [CrossRef]
  40. Patil, K.R.; Nielsen, J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc. Natl. Acad. Sci. USA 2005, 102, 2685–2689. [Google Scholar] [CrossRef] [Green Version]
  41. Aguirre-Gamboa, R.; Gomez-Rueda, H.; Martínez-Ledesma, E.; Martínez-Torteya, A.; Chacolla-Huaringa, R.; Rodriguez-Barrientos, A.; Tamez-Peña, J.G.; Treviño, V. SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis. PLoS ONE 2013, 8, e74250. [Google Scholar] [CrossRef] [PubMed]
  42. Wong, N.W.; Chen, Y.; Chen, S.; Wang, X. OncomiR: An online resource for exploring pan-cancer microRNA dysregulation. Bioinformatics 2018, 34, 713–715. [Google Scholar] [CrossRef] [PubMed]
  43. Guo, Y.; Bao, Y.; Ma, M.; Yang, W. Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int. J. Mol. Sci. 2017, 18, 722. [Google Scholar] [CrossRef]
  44. Nagaraj, N.S.; Datta, P.K. Targetting the Transforming Growth factor-beta Signalling Pathway in Human Cancer. Expert Opin. Investig. Drugs 2010, 19, 77–91. [Google Scholar] [CrossRef] [PubMed]
  45. Sevimoglu, T.; Arga, K.Y. The role of protein interaction networks in systems biomedicine. Comput. Struct. Biotechnol. J. 2014, 11, 22–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Blaj, C.; Bringmann, A.; Urbischek, M.; Krebs, S.; Blum, H.; Fröhlich, T.; Arnold, G.J.; Krebs, S.; Blum, H.; Hermeking, H.; et al. ADNP is a repressor of WNT signaling in colon cancer that can be therapeutically induced. Eur. J. Cancer 2016, 61 (Suppl. 1). [Google Scholar] [CrossRef]
  47. Rask, K.; Thorn, M.; Ponten, F.; Kraaz, W.; Sundfeldt, K.; Hedin, L.; Enerbäck, S. Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int. J. Cancer 2000, 86, 337–343. [Google Scholar] [CrossRef]
  48. Yin, J.; Oh, Y.T.; Kim, J.Y.; Kim, S.S.; Choi, E.; Kim, T.H.; Hong, J.H.; Chang, N.; Cho, H.J.; Sa, J.K.; et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling. Cancer Res. 2017, 77, 4973–4984. [Google Scholar] [CrossRef] [PubMed]
  49. Balcerczak, E.; Pasz-Walczak, G.; Kumor, P.; Panczyk, M.; Kordek, R.; Wierzbicki, R.; Mirowski, M. Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur. J. Surg. Oncol. 2005, 31, 721–726. [Google Scholar] [CrossRef]
  50. Porter, T.R.; Richards, F.M.; Houlston, R.S.; Evans, D.G.R.; Jankowski, J.A.; Macdonald, F.; Norbury, G.; Payne, S.J.; Fisher, S.A.; Tomlinson, I.; et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene 2002, 21, 1928–1933. [Google Scholar] [CrossRef] [Green Version]
  51. Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr. 2001, 131, 2197–2203. [Google Scholar] [CrossRef] [PubMed]
  52. Pek, M.; Yatim, S.M.J.M.; Chen, Y.; Li, J.; Gong, M.; Jiang, X.; Zhang, F.; Zheng, J.; Wu, X.; Yu, Q.; et al. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene 2017, 36, 4975–4986. [Google Scholar] [CrossRef]
  53. Tomonaga, T.; Matsushita, K.; Yamaguchi, S. Overexpression and Mistargeting of Centromere Protein-A in Human Primary Colorectal Cancer. Cancer Res. 2003, 63, 3511–3516. [Google Scholar] [PubMed]
  54. Tomonaga, T.; Matsushita, K.; Ishibashi, M.; Nezu, M.; Shimada, H.; Ochiai, T.; Yoda, K.; Nomura, F. Centromere protein H Is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res. 2005, 65, 4683–4689. [Google Scholar] [CrossRef] [PubMed]
  55. Maruyama, T.; Farina, A.; Dey, A.; Cheong, J.; Bermudez, V.P.; Tamura, T.; Sciortino, S.; Shuman, J.; Hurwitz, J.; Ozato, K.; et al. A Mammalian Bromodomain Protein, Brd4, Interacts with Replication Factor C and Inhibits Progression to S Phase. Mol. Cell. Biol. 2002, 22, 6509–6520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Da Costa, D.; Agathanggelou, A.; Perry, T.; Weston, V.; Petermann, E.; Zlatanou, A.; Oldreive, C.; Wei, W.; Stewart, G.; Longman, J.; et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013, 3, e126. [Google Scholar] [CrossRef]
  57. Dang, C.V.; Le, A.; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 2009, 15, 6479–6483. [Google Scholar] [CrossRef]
  58. Sikora, K.; Chan, S.; Evan, G.; Gabra, H.; Markham, N.; Stewart, J.; Watson, J. c-myc oncogene expression in colorectal cancer. Cancer 1987, 59, 1289–1295. [Google Scholar] [CrossRef] [Green Version]
  59. Castell, A.; Larsson, L.-G. Targeting MYC Translation in Colorectal Cancer. Cancer Discov. 2015, 5, 701–703. [Google Scholar] [CrossRef] [Green Version]
  60. Hellwig, D.; Emmerth, S.; Ulbricht, T.; Doring, V.; Hoischen, C.; Martin, R.; Samora, C.P.; McAinsh, A.D.; Carroll, C.W.; Straight, A.F.; et al. Dynamics of CENP-N kinetochore binding during the cell cycle. J. Cell Sci. 2011, 124, 3871–3883. [Google Scholar] [CrossRef] [Green Version]
  61. Jenster, G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. 1999, 26, 407–421. [Google Scholar] [PubMed]
  62. Seth, A.; Watson, D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 2005, 41, 2462–2478. [Google Scholar] [CrossRef]
  63. Chen, L.; Jiang, B.; Wang, Z.; Liu, M.; Ma, Y.; Yang, H.; Xing, J.; Zhang, C.; Yao, Z.; Zhang, N.; et al. Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer. Med. Oncol. 2013, 30, 498. [Google Scholar] [CrossRef] [PubMed]
  64. Zheng, R.; Blobel, G.A. Gata transcription factors and cancer. Genes Cancer 2010, 1, 1178–1188. [Google Scholar] [CrossRef] [PubMed]
  65. Prabhu, L.; Mundade, R.; Wang, B.; Wei, H.; Hartley, A.-V.; Martin, M.; McElyea, K.; Temm, C.J.; Sandusky, G.; Liu, Y.; et al. Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer. Oncotarget 2015, 6, 29396–29412. [Google Scholar] [CrossRef]
  66. Oda, Y.; Ohishi, Y.; Saito, T.; Hinoshita, E.; Uchiumi, T.; Kinukawa, N.; Iwamoto, Y.; Kohno, K.; Kuwano, M.; Tsuneyoshi, M.; et al. Nuclear expression of Y-box-binding protein-I correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J. Pathol. 2003, 199, 251–258. [Google Scholar] [CrossRef] [PubMed]
  67. Le Gouvello, S.; Bastuji-Garin, S.; Aloulou, N.; Mansour, H.; Chaumette, M.T.; Berrehar, F.; Seikour, A.; Charachon, A.; Karoui, M.; Leroy, K.; et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57, 772–779. [Google Scholar] [CrossRef] [Green Version]
  68. Nevins, J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 2001, 10, 699–703. [Google Scholar] [CrossRef] [Green Version]
  69. Garneau, H.; Paquin, M.C.; Carrier, J.C.; Rivard, N. E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J. Cell. Physiol. 2009, 221, 350–358. [Google Scholar] [CrossRef]
  70. Zhang, T.; Cui, G.; Bi, H.; Shi, H. PRDM14 Promotes the Migration of Human Non-small Cell Lung Cancer Through Extracellular Matrix Degradation in vitro. Chin. Med. J. 2015, 128, 373–377. [Google Scholar] [CrossRef]
  71. Nishikawa, N.; Toyota, M.; Suzuki, H.; Honma, T.; Fujikane, T.; Ohmura, T.; Ohe-Toyota, M.; Maruyama, R.; Sonoda, T.; Sasaki, Y.; et al. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 2007, 67, 9649–9657. [Google Scholar] [CrossRef] [PubMed]
  72. Holst, F.; Stahl, P.R.; Ruiz, C.; Hellwinkel, O.; Jehan, Z.; Wendland, M.; Lebeau, A.; Terracciano, L.; Al-Kuraya, K.; Jänicke, F.; et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 2007, 39, 655–660. [Google Scholar] [CrossRef] [PubMed]
  73. Hrašovec, S.; Glavač, D. MicroRNAs as novel biomarkers in colorectal cancer. Front. Genet. 2012, 3, 180. [Google Scholar] [CrossRef] [PubMed]
  74. Mullany, L.E.; Herrick, J.S.; Sakoda, L.C.; Samowitz, W.; John, R.; Wolff, R.K.; Slattery, M.L. miRNA involvement in cell cycle regulation in colorectal cancer cases. Genes Cancer 2018, 9, 53–65. [Google Scholar] [CrossRef] [PubMed]
  75. Wu, K.; Zhao, Z.; Ma, J.; Chen, J.; Peng, J.; Yang, S.; He, Y. Deregulation of miR-193b affects the growth of colon cancer cells via transforming growth factor-β and regulation of the SMAD3 pathway. Oncol. Lett. 2017, 13, 2557–2562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Trevisani, F.; Ghidini, M.; Larcher, A.; Lampis, A.; Lote, H.; Manunta, P.; Librandi, M.T.; Zagato, L.; Citterio, L.; Dell’Antonio, G.; et al. MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. Br. J. Cancer 2016, 115, 1343–1350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Schee, K.; Lorenz, S.; Worren, M.M.; Günther, C.C.; Holden, M.; Hovig, E.; Fodstad, O.; Meza-Zepeda, L.A.; Flatmark, K. Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer. PLoS ONE 2013, 8, e66165. [Google Scholar] [CrossRef]
  78. Wang, J.; Liu, L.; Sun, Y.; Xue, Y.; Qu, J.; Pan, S.; Li, H.; Qu, H.; Wang, J.; Zhang, J. miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer. Biomed. Pharmacother. 2018, 101, 406–413. [Google Scholar] [CrossRef]
Medicina 55 00020 g001 550
Figure 1. The integrative analytical pipeline employed in the present study. (A) The colorectal cancer (CRC) datasets were analyzed under the Bioconductor platform in R. We used linear models for microarray data (LIMMA) to detect the differentially expressed genes (DEGs) in CRC compared to normal samples. (B) Gene ontology (GO) terms and molecular pathways were identified by DEGs enrichment via the Database for Annotation, Visualization and Integrated Discovery (DAVID). (C) The hub proteins were identified by protein–protein interaction (PPI) analysis. (D) The reporter feature algorithm was used to identify reporter biomolecules as transcriptional regulatory elements. (E) The survival analysis of the hub biomolecules was done through The Cancer Genome Atlas (TCGA) CRC datasets via SurvExpress and oncomiR. (F) The candidate drug molecules were identified by Connectivity Map (cMap) and geneXpharma.
Figure 1. The integrative analytical pipeline employed in the present study. (A) The colorectal cancer (CRC) datasets were analyzed under the Bioconductor platform in R. We used linear models for microarray data (LIMMA) to detect the differentially expressed genes (DEGs) in CRC compared to normal samples. (B) Gene ontology (GO) terms and molecular pathways were identified by DEGs enrichment via the Database for Annotation, Visualization and Integrated Discovery (DAVID). (C) The hub proteins were identified by protein–protein interaction (PPI) analysis. (D) The reporter feature algorithm was used to identify reporter biomolecules as transcriptional regulatory elements. (E) The survival analysis of the hub biomolecules was done through The Cancer Genome Atlas (TCGA) CRC datasets via SurvExpress and oncomiR. (F) The candidate drug molecules were identified by Connectivity Map (cMap) and geneXpharma.
Medicina 55 00020 g001
Medicina 55 00020 g002 550
Figure 2. Identification of differentially expressed genes (DEGs) in colorectal cancer (CRC) from microarray CRC datasets: (A) the upregulated genes in the CRC expression profiling datasets; (B) the downregulated genes in the CRC expression profiling datasets.
Figure 2. Identification of differentially expressed genes (DEGs) in colorectal cancer (CRC) from microarray CRC datasets: (A) the upregulated genes in the CRC expression profiling datasets; (B) the downregulated genes in the CRC expression profiling datasets.
Medicina 55 00020 g002
Medicina 55 00020 g003 550
Figure 3. The significant pathways altered in colorectal cancer: (A) upregulated pathways in colorectal cancer; (B) downregulated pathways in colorectal cancer.
Figure 3. The significant pathways altered in colorectal cancer: (A) upregulated pathways in colorectal cancer; (B) downregulated pathways in colorectal cancer.
Medicina 55 00020 g003
Medicina 55 00020 g004 550
Figure 4. The survival analysis of the hub genes in the prognosis of colorectal cancer. (A) The box-plot represents the differential expression of the 10 hub genes in two risks groups. (B) The Kaplan–Meier plot represents the prognostic ability of the hub gene signatures in CRC.
Figure 4. The survival analysis of the hub genes in the prognosis of colorectal cancer. (A) The box-plot represents the differential expression of the 10 hub genes in two risks groups. (B) The Kaplan–Meier plot represents the prognostic ability of the hub gene signatures in CRC.
Medicina 55 00020 g004
Medicina 55 00020 g005 550
Figure 5. The survival assessment of the reporter transcription factor (TF) signatures in the prognosis of colorectal cancer. (A) The box-plot represents the differential expression of the 10 TFs between both risk groups. (B) The Kaplan–Meier plot represents the prognostic power of the TF signatures in colorectal cancer.
Figure 5. The survival assessment of the reporter transcription factor (TF) signatures in the prognosis of colorectal cancer. (A) The box-plot represents the differential expression of the 10 TFs between both risk groups. (B) The Kaplan–Meier plot represents the prognostic power of the TF signatures in colorectal cancer.
Medicina 55 00020 g005
Medicina 55 00020 g006 550
Figure 6. The survival analysis of the reporter microRNA (miRNA) signatures in colorectal cancer. The Kaplan–Meier plot represents the prognostic ability of miRNA signatures (miR-193b-3p and miR-615-3p) in colorectal cancer.
Figure 6. The survival analysis of the reporter microRNA (miRNA) signatures in colorectal cancer. The Kaplan–Meier plot represents the prognostic ability of miRNA signatures (miR-193b-3p and miR-615-3p) in colorectal cancer.
Medicina 55 00020 g006
Medicina 55 00020 g007 550
Figure 7. Drug repositioning results in colorectal cancer. (A) Classification of repurposed drugs according to drug development stages. (B) Distribution of approved drugs into anatomical therapeutic chemical drug classes.
Figure 7. Drug repositioning results in colorectal cancer. (A) Classification of repurposed drugs according to drug development stages. (B) Distribution of approved drugs into anatomical therapeutic chemical drug classes.
Medicina 55 00020 g007
Table
Table 1. Functional overrepresentation of differentially expressed genes in colorectal cancer (CRC).
Table 1. Functional overrepresentation of differentially expressed genes in colorectal cancer (CRC).
Gene OntologyGene Ontology (GO) Term# of GenesCoverage (%)p-Value
Upregulated genes
Biological ProcessCollagen fibril organization111.624.53 × 10−7
Extracellular matrix organization223.242.94 × 10−6
Male gonad development142.061.53 × 10−5
Positive regulation of transcription from RNA polymerase II promoter588.563.90 × 10−5
Collagen catabolic process111.625.07 × 10−5
Cellular ComponentExtracellular region8412.42.40 × 10−5
Cytoplasm21631.95.80 × 10−5
Extracellular space7010.31.50 × 10−4
Basement membrane111.622.56 × 10−4
Extracellular matrix233.393.34 × 10−4
Molecular FunctionProtein binding35452.38.10 × 10−8
Protein homodimerization activity426.207.54 × 10−4
Growth factor activity152.211.04 × 10−3
Extracellular matrix binding60.881.47 × 10−3
Amino-acid transmembrane transporter activity71.034.43 × 10−3
Downregulated genes
Biological ProcessBicarbonate transport54.905.89 × 10−5
One-carbon metabolic process43.924.00 × 10−4
Chloride transmembrane transport54.901.06 × 10−3
Nervous system development76.862.63 × 10−3
Regulation of chloride transport21.969.62 × 10−3
Cellular ComponentPlasma membrane3130.40.0108
Extracellular space1413.70.0135
Integral component of membrane3635.30.0163
Anchored component of membrane43.920.0179
Integral component of plasma membrane1312.70.0421
Molecular FunctionCarbonate dehydratase activity43.924.16×10−5
Hormone activity54.900.0012
Zinc ion binding1514.70.0018
UDP-galactose:β-N-acetylglucosamine β-1,3-galactosyltransferase activity32.940.0018
Chloride channel activity43.920.0025
Table
Table 2. Summary of hub proteins in colorectal cancer.
Table 2. Summary of hub proteins in colorectal cancer.
SymbolDescriptionFeature
Hub proteins
ADNPActivity-dependent neuroprotector homeoboxStimulatory and inhibitory effect on the growth of tumor cells
CEBPBCCAAT/enhancer-binding protein betaInvolved in immune and inflammatory responses
CCND1Cyclin D1 (afflicted with cancers colonic adenocarcinomas, myeloma)Cell-cycle regulatory protein
CD44CD44 moleculeRequired in cell–cell interactions, migration
CDK4Cyclin-dependent kinase 4Cyclin D1 activates CDK4, which causes proliferation of cellular division.
CENPACentromere protein A (afflicted with colorectal cancer)Central role in the assembly of kinetochore
CENPHCentromere Protein H (afflicted with colorectal cancer)Central role in the assembly of kinetochore proteins
RFC2Replication factor C subunit 2Encodes activator 1 small subunit family
MYCMyc proto-oncogeneRegulator gene contributes to formation of many human cancers
CENPNCentromere protein NInvolved in cell-cycle process
Table
Table 3. Summary of reporter regulators in colorectal cancer.
Table 3. Summary of reporter regulators in colorectal cancer.
SymbolDescriptionFeature
Reporter Transcription Factors
ARAndrogen receptorInvolved in prostate cancer
GATA1GATA binding protein 1Transcriptional activator or repressor
GATA2GATA binding protein 2 (afflicted with colorectal cancer)Transcriptional activator
GATA3GATA binding protein 3Transcriptional activator
E2F4E2F transcription factor 4Controls of cell cycle
ETS1ETS proto-oncogene 1Involved in tumorigenesis
YBX1Y-box binding protein 1Aberrant expression is associated with cancer
PRADM14PR/SET domain 14Involved in breast cancer
ESR1Estrogen receptor 1Involved in breast cancer
FOXP3Forkhead box P3 (afflicted with colorectal cancer)DNA binding
Reporter microRNAs
miR-193b-3pMicroRNA 193Afflicted with CRC and epidermal squamous cell carcinoma
miR-615-3pMicroRNA 615Afflicted with CRC
miR-16-5pMicroRNA 16Potential biomarkers in gastric cancer
miR-26b-5pMicroRNA 26Afflicted with CRC
let-7b-5pMicroRNA 7Afflicted with CRC
miR-92a-3pMicroRNA 92Afflicted with CRC
miR-124-3pMicroRNA 124Afflicted with CRC, gastric and breast cancer
miR-484MicroRNA 484Afflicted with CRC
miR-192-5pMicroRNA 192Afflicted with CRC
miR-93-5pMicroRNA 93Afflicted with head and neck cancer
Table
Table 4. Selected repositioned drugs in colorectal cancer.
Table 4. Selected repositioned drugs in colorectal cancer.
TargetRepositioned DrugDrug Class/Status/Description
   Hub protein
CCND1GefitinibAntineoplastic agent; approved; investigational/used in the treatment of cancer
HydrocortisoneAnti-inflammatory agent; approved; used in the treatment of inflammation, allergy, collagen diseases, asthma, and some neoplastic conditions
IrinotecanAntineoplastic agent; approved; investigational/used in the treatment of colorectal cancer
LetrozoleAntineoplastic agent; approved; investigational/introduced for treatment of breast cancer
LidocaineAnesthetic; approved; local anesthetic and used as an antiarrhythmia agent
MethotrexateAntimetabolite, antineoplastic; approved; antineoplastic antimetabolite with immunosuppressant properties
SirolimusAntineoplastic and immunomodulating agents; approved; investigational/a potent immunosuppressant which possesses both antifungal and antineoplastic properties
TamoxifenAntineoplastic and immunomodulating agent; approved; for the treatment and prevention of breast cancer
CDK4GefitinibAntineoplastic agent; approved; investigational/used in the treatment of cancer
LidocaineAnesthetic; approved; local anesthetic and used as an antiarrhythmia agent
SirolimusAntineoplastic and immunomodulating agent; approved; investigational/a potent immunosuppressant which possesses both antifungal and antineoplastic properties
MYCGefitinibAntineoplastic agent; approved; investigational/used in the treatment of cancer
TamoxifenAntineoplastic and immunomodulating agent; approved; for the treatment and prevention of breast cancer
SimvastatinCardiovascular system; approved; a lipid-lowering agent
   Reporter TFs
GATA3AzathioprineAntineoplastic and immunomodulating agent; approved; immunosuppressive antimetabolite pro-drug
DaunorubicinAntineoplastic and immunomodulating agent; approved; used in treatment of leukemia and other neoplasms
DexamethasoneAntineoplastic agent; approved, investigational, vet approved; for the treatment of endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases
DoxorubicinAntineoplastic and immunomodulating agent; approved; investigational/used neoplastic conditions like acute lymphoblastic leukemia
MercaptopurineAntimetabolite antineoplastic agent with immunosuppressant properties; approved; in the treatment of leukemia
MethotrexateAntimetabolite, antineoplastic; approved; antineoplastic antimetabolite with immunosuppressant properties
ESR1ClomifeneEstrogen agonist, antagonist; approved; investigational/used mainly in female infertility due to anovulation to induce ovulation
DaunorubicinAntineoplastic and immunomodulating agent; approved; used in treatment of leukemia and other neoplasms
DexamethasoneAntineoplastic agent; approved; investigational/for the treatment of endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases
EstriolEstradiol congener; approved; investigational/used as a test to determine the general health of an unborn fetus
EstroneHormone; approved; used for management of perimenopausal and postmenopausal symptoms
EtoposideAntineoplastic agent; approved; used in the treatment of refractory testicular tumors and in patients with small cell lung cancer
FulvestrantAntineoplastic and immunomodulating agent; approved; investigational/a drug treatment of metastatic breast cancer
GlibenclamideOral hypoglycemic; approved; used for the treatment of non-insulin-dependent diabetes mellitus
ImipramineCentral nervous system agent; approved; antidepressant used for the relief of symptoms of depression
LetrozoleAntineoplastic agent; approved; investigational/introduced for the treatment of breast cancer
MegestrolAntineoplastic and immunomodulating agent; approved; investigational/used in the palliative treatment of breast cancer
MifepristoneAbortifacient agent and blood-glucose-lowering agent; approved; investigational/for the medical termination of intrauterine pregnancy; also indicated to control hyperglycemia
ProgesteroneContraceptive agent; approved, vet approved; progesterone acts on the uterus, the mammary glands, and the brain
RaloxifeneEstrogen agonist, antagonist; approved; investigational/used to prevent osteoporosis in postmenopausal women
TamoxifenAntineoplastic and immunomodulating agent; approved; for the treatment and prevention of breast cancer
TestosteroneAndrogen and estrogen; approved; investigational/in men, testosterone is produced primarily by the leydig cells of the testes; testerone in women functions to maintain libido and general wellbeing.
ARCyproteroneAntineoplastic agent and hormone antagonist; approved; investigational/used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma
Flufenamic acidAntiinflammatory and antirheumatic; experimental; analgesic, anti-inflammatory, and antipyretic properties
FlutamideAntineoplastic agent, hormonal; approved; investigational/for the management of metastatic carcinoma of the prostate
LevonorgestrelContraceptive agent; approved; investigational/for the treatment of menopausal and postmenopausal disorders
MifepristoneAbortifacient agent and blood-glucose-lowering agent; approved; investigational/for the medical termination of intrauterine pregnancy; also indicated to control hyperglycemia
SpironolactoneAgent causing hyperkalemia; approved; used primarily to treat low-renin hypertension, hypokalemia, and Conn’s syndrome
TestosteroneAndrogen and estrogen; approved; investigational/in men, testosterone is produced primarily by the interstitial cells of the testes; it functions to maintain libido and general wellbeing in women.

Share and Cite

MDPI and ACS Style

Rahman, M.R.; Islam, T.; Gov, E.; Turanli, B.; Gulfidan, G.; Shahjaman, M.; Akhter Banu, N.; Mollah, M.N.H.; Arga, K.Y.; Moni, M.A. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis. Medicina 2019, 55, 20. https://doi.org/10.3390/medicina55010020

AMA Style

Rahman MR, Islam T, Gov E, Turanli B, Gulfidan G, Shahjaman M, Akhter Banu N, Mollah MNH, Arga KY, Moni MA. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis. Medicina. 2019; 55(1):20. https://doi.org/10.3390/medicina55010020

Chicago/Turabian Style

Rahman, Md. Rezanur, Tania Islam, Esra Gov, Beste Turanli, Gizem Gulfidan, Md. Shahjaman, Nilufa Akhter Banu, Md. Nurul Haque Mollah, Kazim Yalcin Arga, and Mohammad Ali Moni. 2019. "Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis" Medicina 55, no. 1: 20. https://doi.org/10.3390/medicina55010020

Article Metrics

Back to TopTop